Name and surname:
|
doc. MUDr. Tomáš Bolek, PhD.
|
Document type:
|
Research/art/teacher profile of a person
|
The name of the university:
|
Comenius University Bratislava
|
The seat of the university:
|
Šafárikovo námestie 6, 818 06 Bratislava
|
III.a - Occupation-position | III.b - Institution | III.c - Duration |
---|---|---|
Secondary Doctor | University hospital in Martin | 2015 - |
assistant | Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava | 2020 - |
asociate profesor | Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava | 2024 - |
IV.a - Activity description, course name, other | IV.b - Name of the institution | IV.c - Year |
---|---|---|
Specialization in Internal Medicine | Jessenius Faculty of Medicine in Martin, Comenius Universtiy in Bratislava | 2020 |
V.1.a - Name of the profile course | V.1.b - Study programme | V.1.c - Degree | V.1.d - Field of study |
---|---|---|---|
Propedeutics of Internal Medicine | General Medicine | I.+II. | General Medicine |
Internal Medicine 1 - 5 | General Medicine | I.+II. | General Medicine |
Propedeutics of Internal Medicine | Dentistry, Dental Medicine | I.+II. | Dentistry, Dental Medicine |
Internal Medicine 1 - 4 | Dentistry, Dental Medicine | I.+II. | Dentistry, Dental Medicine |
V.5.a - Name of the course | V.5.b - Study programme | V.5.c - Degree | V.5.d - Field of study |
---|---|---|---|
Diploma Thesis Semminar 1 - 3 | General Medicine | I.+II. | General Medicine |
Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J, Galajda P, Kubisz P, Mokáň M. The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. Am J Ther 2019; 26: e308-e313. ADC, IF (JCR 2016) 1,588.
Bolek T, Samoš M, Škorňová I, Stančiaková L, Staško J, Galajda P, Kubisz P, Mokáň M.CDabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post Marketing Experiences. Drugs Aging 2018; 35: 539 – 544. ADC, IF (JCR 2016) 2,381.
Bolek T, Samoš M, Škorňová I, Stančiaková L, Staško J, Korpallová B, Galajda P, Kubisz P, Mokáň M. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treatedCpatients with atrial fibrillation? A pilot study. J Thromb Thrombolysis 2019; 47: 140 - 145. ADC, IF (JCR 2019) 2,054.
Samoš M, Fedor M, Kovář F, Galajda P, Bolek T, Stančiaková L, Fedorová J, Staško J, Kubisz P, Mokáň M. The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. J Diabetes Res 2016; 2016:
2909436. ADM, IF (JCR 2016) 2,717.
Bolek T, Samoš M, Škorňová I, Schnierer M, Lipták P, Bánovčin P, Urban L, Staško J, Kubisz P, Galajda P, Mokán M. Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference? Eur J Clin Pharmacol 2019; 75: 875 - 877.
Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J, Galajda P, Kubisz P, Mokáň M. The Impact of Proton Pump Inhibition on Dabigatran Levels in Patients With Atrial Fibrillation. Am J Ther 2019; 26: e308-e313. ADC, IF (JCR 2016) 1,588.
Bolek T, Samoš M, Škorňová I, Stančiaková L, Staško J, Galajda P, Kubisz P, Mokáň M.CDabigatran Levels in Elderly Patients with Atrial Fibrillation: First Post Marketing Experiences. Drugs Aging 2018; 35: 539 – 544. ADC, IF (JCR 2016) 2,381.
Bolek T, Samoš M, Škorňová I, Stančiaková L, Staško J, Korpallová B, Galajda P, Kubisz P, Mokáň M. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treatedCpatients with atrial fibrillation? A pilot study. J Thromb Thrombolysis 2019; 47: 140 - 145. ADC, IF (JCR 2019) 2,054.
Samoš M, Fedor M, Kovář F, Galajda P, Bolek T, Stančiaková L, Fedorová J, Staško J, Kubisz P, Mokáň M. The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. J Diabetes Res 2016; 2016:
2909436. ADM, IF (JCR 2016) 2,717.
Bolek T, Samoš M, Škorňová I, Schnierer M, Lipták P, Bánovčin P, Urban L, Staško J, Kubisz P, Galajda P, Mokán M. Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference? Eur J Clin Pharmacol 2019; 75: 875 - 877.
Chan, N. C. - Coppens, M. - Hirsh, J. - Ginsberg, J. S. - Weitz, J. I. - Vanassche, T. - Douketis, J. D. - Schulman, S. - Eikelboom, J. W.: Journal of Thrombosis and Haemostasis, roč. 13, č. 3, 2015, s. 353-359 - SCI ; SCOPUS
Douketis, J. D. - Wang, G. - Chan, N. - Eikelboom, J. W. - Syed, S. - Barty, R. - Moffat, K. A. - Spencer, F. A. - Blostein, M. - Schulman, S.: Journal of Thrombosis and Haemostasis, roč. 14, č. 1, 2016, s. 89-97 - SCI ; SCOPUS
Warkentin, T. E. - Pai, M. - Linkins, L. A.: Blood, roč. 130, č. 9, 2017, s. 1104-1113 - SCI ; SCOPUS
Wang, N. - Chen, L. - Li, N. - Xu, G. - Qi, F. - Zhu, L. - Liu, W.: Scientific Reports, roč. 10, č. 1, 2020, čl. č. 9717 - SCI ; SCOPUS
Shin, H. J. - Boo, G. - Na, H. S.: Journal of Anesthesia, roč. 35, č. 5, 2021, s. 633-637 - SCI ; SCOPUS
APVV 16-00-20 Specific laboratory monitoring of platelets reactivity in patients with acute myocardial infarction treated by new antagonists of P2Y12 receptors (Co-Investigator)
VEGA 1/0549/19 Applications of results of DNA analyse and microRNA detection in primary and secondary proplylaxis of thromboembolic complications in patients with sticky platelet syndrome (Co-Investigator).
VEGA 1/0090/20 (2020 – 2022) New trends in treatment and new markers of progression of chronic heart disease with preserved ejection function im patients with type 2 diabetes mellitus. Research of risk factors of chronic heart failure with preserved ejection fraction in patients with obesity and type 2 diabetes mellitus (Co-Investigator).
European Structural and Investment Funds ITMS2014+:313011V344 (2019 – 2023) Long-term strategic research of prevention, intervention and mechanisms of obesity and its comorbidities. Activity – Mechanisms and markers of obesity and its comorbidities – research of microRNA as biomarkers (Co-investigator).